25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future

D'Haens GR, van Deventer S

Published Jul 2021, in the Gut

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN.

Published Jul 2021, in the Clinical gastroenterology and hepatology

Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents

van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL

Published Jun 2021, in the Alimentary pharmacology & therapeutics.

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

Sandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S.

Published Jun 2021, in the Inflammatory bowel diseases.

Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic

Goodsall TM, Han S, Bryant RV.

Published Jun 2021, in the Journal of gastroenterology and hepatology

Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease

Sinh P, Cross R.

Published Jun 2021, in the Inflammatory bowel diseases.

Vaccinations in patients with inflammatory bowel disease

Macaluso FS, Liguori G, Galli M.

Published Jun 2021, in the Digestive and liver disease.

Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome

Bolte LA, Vich Vila A, Imhann F, Collij V, Gacesa R, Peters V, Wijmenga C, Kurilshikov A, Campmans-Kuijpers MJE, Fu J, Dijkstra G, Zhernakova A, Weersma RK

Published Jul 2021, in the Gut

Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial

Taku Kobayashi, Satoshi Motoya, Shiro Nakamura, Takayuki Yamamoto, Masakazu Nagahori, Shinji Tanaka, Tadakazu Hisamatsu, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Takayuki Matsumoto, Masanori Tanaka, Takayuki Abe, Yasuo Suzuki , Mamoru Watanabe, Hiroyuki Imaeda, Shingo Kato, Atsushi Maemoto, Minoru Matsuura, Ryosuke Sakemi, Makoto Sasaki, Tomoyuki Tsujikawa, Motohiro Esaki, Norimasa Fukata, Kazuya Kitamura, Sakiko Hiraoka, Ryota Hokari, Shunji Ishihara, Tsutomu Mizoshita, Yuji Naito, Fumio Omata, Masayuki Saruta, Takuya Yoshino

​Published April 2021 in the The Lancet Gastroenterology & Hepatology 

Long-term dietary patterns are associated with pro- inflammatory and anti-inflammatory features of the gut microbiome.

Laura A Bolte, Arnau Vich Vila, Floris Imhann, Valerie Collij,Ranko Gacesa, Vera Peters, Cisca Wijmenga, Alexander Kurilshikov, Marjo J E Campmans-Kuijpers, Jingyuan Fu, Gerard Dijkstra, Alexandra Zhernakova, Rinse K Weersma.

Published in BMJ journals